Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

OliX and Eli Lilly announced a global licensing agreement, focusing on the development and commercialization of OliX’s ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Atalanta aims to create disease-modifying therapies by silencing certain genes in the central nervous system, including in the brain and spinal cord.

LONDON, Feb. 05, 2025 (GLOBE NEWSWIRE) -- e-therapeutics plc, a company integrating computational power and biological data to discover ...